Back to search

Article

Proteogenomic characterization of the non-muscle-invasive bladder cancer response to BCG reveals potential therapeutic strategies

2024-03-06

Abstract excerpt

<h4>Background: </h4> Intravesical bacillus Calmette-Guérin (BCG) is the standard therapy for adjuvant treatment in patients with intermediate- and high-risk superficial bladder cancer. However, the molecular properties associated with BCG therapy have not been fully characterized. Methods We reported a comprehensive proteogenomic analysis, including whole-genome sequencing, proteomics, and phosphoproteomics prof...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
688aba85-91a8-58e3-89c8-207e0d7fd8ef
DOI
10.21203/rs.3.rs-4008035/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Proteogenomic characterization of the non-muscle-invasive bladder cancer response to BCG reveals potential therapeutic strategiesDOI 10.21203/rs.3.rs-4008035/v1
Genomic and Therapeutic Landscape of Non-muscle-invasive Bladder Cancer.Semantic proximity
Comprehensive Landscape of Non-muscle Invasive Bladder Cancer Tumour Microenvironment and Prognostic value of Cancer-Associated MyofibroblastsSemantic proximity
Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non-Muscle-Invasive Bladder Cancer.Semantic proximity
An integrated molecular classification system identifies distinct prognostic clusters of non-muscle-invasive bladder cancer.Semantic proximity
Multi-omics consensus ensemble refines the classification of muscle-invasive bladder cancer with stratified prognosis, tumour microenvironment and distinct sensitivity to frontline therapiesSemantic proximity
Combined exome and transcriptome sequencing of non-muscle-invasive bladder cancer: associations between genomic changes, expression subtypes, and clinical outcomesSemantic proximity
Molecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancerSemantic proximity
Advances in immunotherapy for bladder cancer and clinical practice of next-generation sequencing.Semantic proximity
Discovery of Molecular DNA Methylation-Based Biomarkers through Genome-Wide Analysis of Response Patterns to BCG for Bladder CancerSemantic proximity
Elevated T-cell exhaustion and urinary tumor DNA levels are associated with BCG failure in patients with non-muscle invasive bladder cancerSemantic proximity
The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder CancerSemantic proximity
Pyroptosis-related subtypes predict the prognosis, tumor immune microenvironment and guide chemotherapy and immunotherapy in bladder cancerSemantic proximity
Select a neighboring publication to make it the new centre.